Google
Trusted Resources: News & Events
Latest announcements and gatherings
Boston Children’s Hospital receives grant for sickle cell disease research
The Bill and Melinda Gates Foundation awarded a $1.5 million grant to Boston Children’s Hospital to research and develop gene therapy treatment for sickle cell disease.
The research will be directed toward gene therapy methods that can be applied in developing regions of the world, where sickle cell disease incidence is high.
“While gene therapies are currently confined to a few research hospitals in the U.S. and other developed countries, our long-term goal is to make this treatment available to patients in developing countries — and we have already begun to think about how to translate this specialized, potentially curative therapy,” David A. Williams, MD, chief scientific officer and senior vice president of Boston Children’s Hospital and president of Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, said in a press release.
+myBinderRelated Content
-
Successful Gene Therapy for Sickle Cell DiseasePrior to this report, the only curative ...
-
CIRM and NHLBI Collaborating to Fund Cell and Gene Therapies for Sickle Cell DiseaseThe California Institute for Regenerativ...
-
CRISPR deployed to combat sickle-cell anaemiaA mutation in a single DNA letter causes...
-
Gene therapy targets sickle-cell diseaseElliott Vichinsky estimates that at leas...
-
Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickl...Although allogeneic haematopoietic stem ...
-
3 Gene Editing Approaches for Sickle Cell DiseaseSickle cell disease (SCD) is a perfect c...
-
Gene Therapy & Clinical Trials Webinarhttps://www.youtube.com/watch?v=yYexIUgH...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.